Cargando…

Who Needs XR, LA, SR, XL, ER, or CR?

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2005
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437516/ https://www.ncbi.nlm.nih.gov/pubmed/16300421 http://dx.doi.org/10.18553/jmcp.2005.11.9.772

Ejemplares similares

Who Needs Another Clinical Practice Guideline?
por: Curtiss, Frederic R.
Publicado: (2004)

Dosimetric evaluation of GAFCHROMIC® XR type T and XR type R films
por: Dini, Sharifeh A., et al.
Publicado: (2005)

Medication Therapy Management Programs - Will Patient Need be Satisfied
por: Curtiss, Frederic R.
Publicado: (2005)

Ultraviolet exposure of Gafchromic XR‐RV3 and XR‐SP2 films
por: Katsuda, Toshizo, et al.
Publicado: (2015)

Structures and Magnetic Ordering in Layered Cr Oxide Arsenides Sr(2)CrO(2)Cr(2)OAs(2) and Sr(2)CrO(3)CrAs
por: Sheath, Bradley C., et al.
Publicado: (2022)

The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
por: De Freitas, Ovidio, et al.
Publicado: (2006)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Cisco IOS XR fundamentals
por: Tahir, Mobeen
Publicado: (2009)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells
por: Greer, Lacey K., et al.
Publicado: (2022)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

XR Programmers Give Their Perspective on How XR Technology can be Effectively Utilised in High-Performance Sport
por: Le Noury, Peter J., et al.
Publicado: (2023)

Who needs an editor?
por: Westgarth, David
Publicado: (2023)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Who needs registered reports?
por: Robertson, Miranda
Publicado: (2017)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

In Search of Safe and Effective Oral Anticoagulation
por: Curtiss, Frederic R.
Publicado: (2005)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

(LaCrO(3))(m)/SrCrO(3) superlattices as transparent p-type semiconductors with finite magnetization
por: Tyagi, Shubham, et al.
Publicado: (2023)

Reduction of Artefacts in JPEG-XR Compressed Images
por: Hua, Kai-Lung, et al.
Publicado: (2019)

Directional translocation resistance of Zika xrRNA
por: Suma, Antonio, et al.
Publicado: (2020)

Quality Improvement Opportunities in Prescriber Alert Programs
por: Curtiss, Frederic R.
Publicado: (2010)

What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
por: Curtiss, Frederic R.
Publicado: (2006)

Measuring Value in the Treatment of Symptoms of Allergic Rhinitis With Nasal Steroids
por: Curtiss, Frederic R.
Publicado: (2006)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Perspectives on the Generic Cliff--Pushing and Falling
por: Curtiss, Frederic R.
Publicado: (2008)

Irritable Bowel Syndrome and Antidepressants
por: Curtiss, Frederic R.
Publicado: (2008)

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management
por: Curtiss, Frederic R.
Publicado: (2009)

HEDIS, Beta-Blockers, and What More Can Be Done to Improve Secondary Prevention in ACS
por: Curtiss, Frederic R.
Publicado: (2008)

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006)

Atopic March to a Dead End or Does the Theory Really Have Legs?
por: Curtiss, Frederic R.
Publicado: (2007)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Quality of Health Economic Studies (QHES) - Tool or Mask?
por: Curtiss, Frederic R.
Publicado: (2003)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003)

Medicare PPOs and Managed Care
por: Curtiss, Frederic R.
Publicado: (2003)

Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)

Looking for the Outcomes We Love in All the Wrong Places: The Questionable Value of Biomarkers and Investments in Chronic Care Disease Management Interventions
por: Curtiss, Frederic R.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_g803f537dcnq3qnsiu5hdenk01